Expert: Anti-TA-MUC1 ADC with DXd payload targeting tumor-associated MUC1 glycoform. Potential for broad solid tumor application.

Everyday: An antibody-drug conjugate that targets a tumor-specific form of MUC1 protein found on various solid tumors.

Targets: ["TA-MUC1"]

TA-MUC1-directed ADC. Daiichi-only program (not partnered with AZN or Merck). Early stage development.